RecruitingNot ApplicableNCT07523438

Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery

Effect of Two Different Doses of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery , A Randomized Clinical Trial


Sponsor

Alexandria University

Enrollment

120 participants

Start Date

Mar 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg /kg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg/kg


Eligibility

Min Age: 3 YearsMax Age: 6 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying high dex group and low dex group for people with dexmedetomidine and emergence agitation. The study is currently recruiting participants at 1 location. People eligible for this study include aged 3 Years to 6 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERhigh dex group

patients will receive 3 mcg/kg intranasal dexmedetomidine 45minutes before surgery

OTHERlow dex group

patients will receive 2 mcg/kg intranasal dexmedetomidine 45minutes before surgery


Locations(1)

Alexandria University

Alexandria, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07523438


Related Trials